13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001858703
Total reported value
$664.5M
$664.5M
72 檔
19.3%
According to the latest 13F quarterly dataset, Blue Owl Capital Holdings LP managed an equity portfolio of $664.5M at the end of Q3 2025, spanning 72 distinct U.S. exchange-listed positions.
In Q3 2025, Blue Owl Capital Holdings LP adopted a defensive or profit-taking posture, trimming 15 positions and completely liquidating 10 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including NCDL, OBDC, ENGENE HOLDINGS INC) accounted for 19.3% of total reported equity market value during Q3 2025.
Top New Position Initiated
DELL
市值: $7.4M
Top Position Liquidated / Trimmed
TRML
前期市值: $15.8M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NCDL | Nuveen Churchill Direct Lend | Stock-Other | 13.24% | -3.32% | -23.47% | |
| 2 | OBDC | Blue Owl Capital CORP | Stock-Financials | 8.11% | -2.73% | — | |
| 3 | ✓ | Engene Holdings Inc | Stock-Other | 6.95% | -8.08% | EXIT | |
| 4 | LRMR | Larimar Therapeutics Inc | Stock-Other | 5.87% | -4.40% | +18.77% | |
| 5 | EVCM | Evercommerce Inc | Stock-Other | 5.67% | — | — | |
| 6 | HLLY | Holley Inc | Stock-Other | 4.74% | -1.81% | +18.24% | |
| 7 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 4.64% | — | — | |
| 8 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 4.62% | -3.07% | +5.24% | |
| 9 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 3.94% | -0.78% | +65.51% | |
| 10 | CNDT | Conduent Inc | Stock-Other | 3.87% | -0.62% | — | |
| 11 | SGMT | Sagimet Biosciences Inc-a | Stock-Other | 2.83% | +1.00% | — | |
| 12 | CMPX | Compass Therapeutics Inc | Stock-Other | 2.82% | -2.99% | — | |
| 13 | DELL | Dell Technologies -c | Stock-Tech | 2.30% | +1.53% | +151.03% | |
| 14 | CVEO | Civeo CORP | Stock-Other | 2.27% | -1.28% | EXIT | |
| 15 | CNTX | Context Therapeutics Inc | Stock-Other | 2.23% | -3.34% | — | |
| 16 | AQST | Aquestive Therapeutics Inc | Stock-Other | 2.17% | -0.91% | +35.87% | |
| 17 | IRON | Disc Medicine Inc | Stock-Other | 2.10% | — | -16.36% | |
| 18 | RPTX | Repare Therapeutics Inc | Stock-Other | 1.88% | — | — | |
| 19 | PVLA | Palvella Therapeutics Inc | Stock-Other | 1.85% | -0.22% | -23.95% | |
| 20 | EYPT | Eyepoint Inc | Stock-Other | 1.62% | -1.52% | -34.66% | |
| 21 | KRRO | Korro Bio Inc | Stock-Other | 1.56% | — | -16.00% | |
| 22 | IMA | Imagenebio Inc | Stock-Other | 1.37% | -0.48% | — | |
| 23 | PLRX | Pliant Therapeutics Inc | Stock-Other | 1.36% | -1.01% | EXIT | |
| 24 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.28% | — | -48.74% | |
| 25 | IMRX | Immuneering CORP - Class A | Stock-Other | 1.20% | — | — | |
| 26 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.19% | — | -69.95% | |
| 27 | CMPS | Compass Pathways PLC | Stock-Other | 1.08% | +0.96% | NEW | |
| 28 | ✓ | Adc Therapeutics SA | Stock-Other | 0.91% | -0.58% | — | |
| 29 | NU | Nu Holdings Ltd. | Stock-Financials | 0.86% | — | — | |
| 30 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.80% | — | — | |
| 31 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 0.79% | -0.84% | -26.32% | |
| 32 | ACLXGBX | Arcellx Inc | Stock-Other | 0.68% | — | — | |
| 33 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.47% | -1.16% | EXIT | |
| 34 | FLD | Fold Holdings Inc | Stock-Other | 0.45% | -0.24% | — | |
| 35 | NIOBW | Niocorp Developments LTD -28 | Stock-Other | 0.31% | -0.08% | — | |
| 36 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.31% | — | -85.34% | |
| 37 | EPD | Enterprise Products Partners | Stock-Energy | 0.30% | -0.32% | EXIT | |
| 38 | GTLB | Gitlab Inc-cl A | Stock-Tech | 0.17% | — | — | |
| 39 | SHFS | Shf Holdings Inc | Stock-Other | 0.17% | -0.02% | — | |
| 40 | TTAN | Servicetitan Inc-a | Stock-Tech | 0.16% | — | -56.35% | |
| 41 | MRKR | Marker Therapeutics Inc | Stock-Other | 0.15% | -0.07% | — | |
| 42 | ✓ | Rezolve Ai LTD | Stock-Other | 0.15% | -0.02% | -38.55% | |
| 43 | ✓ | Alpha Modus Hldgs Inc | Stock-Other | 0.14% | -0.04% | EXIT | |
| 44 | CAH | Cardinal Health Inc | Stock-Healthcare | 0.08% | -0.10% | EXIT | |
| 45 | 62C | Piper Sandler Cos | Stock-Other | 0.07% | — | — | |
| 46 | SLND-WS | Legato Merger CORP Ii -cw23 | Stock-Other | 0.05% | -0.01% | — | |
| 47 | AMODW | Insight Acquisition Co -cw23 | Stock-Other | 0.04% | -0.01% | — | |
| 48 | ✓ | Blue Gold LTD | Stock-Other | 0.02% | -0.01% | — | |
| 49 | OPTXW | Omnilit Acquisition Cl A -23 | Stock-Other | 0.02% | -0.23% | EXIT | |
| 50 | BKSY-WS | Blacksky Technology -cw24 | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ROIV | Roivant Sciences Ltd. | +4.5% | — | Add |
| 2 | LRMR | Larimar Therapeutics Inc | +2.6% | +18.77% | Add |
| 3 | ✓ | Engene Holdings Inc | +2.2% | -12.07% | Trim |
| 4 | RARE | Ultragenyx Pharmaceutical In | +2.2% | +65.51% | Add |
| 5 | SGMT | Sagimet Biosciences Inc-a | +1.4% | — | Unchanged |
| 6 | AQST | Aquestive Therapeutics Inc | +1.3% | +35.87% | Add |
| 7 | CMPX | Compass Therapeutics Inc | +1% | — | Trim |
| 8 | RPTX | Repare Therapeutics Inc | +0.8% | — | Unchanged |
| 9 | CNTX | Context Therapeutics Inc | +0.8% | — | Add |
| 10 | PVLA | Palvella Therapeutics Inc | +0.6% | -23.95% | Trim |
| 11 | ✓ | Adc Therapeutics SA | +0.6% | — | Unchanged |
| 12 | EVCM | Evercommerce Inc | +0.3% | — | Unchanged |
| 13 | HLLY | Holley Inc | +0.3% | +18.24% | Trim |
| 14 | NIOBW | Niocorp Developments LTD -28 | +0.3% | — | Trim |
| 15 | EYPT | Eyepoint Inc | +0.2% | -34.66% | Trim |
| 16 | MLYS | Mineralys Therapeutics Inc | +0.1% | -69.95% | Trim |
| 17 | ✓ | Rezolve Ai LTD | +0.1% | -38.55% | Trim |
| 18 | PLRX | Pliant Therapeutics Inc | +0.1% | — | Unchanged |
| 19 | SHFS | Shf Holdings Inc | +0.1% | — | Unchanged |
| 20 | CMPS | Compass Pathways PLC | 0% | +163.10% | Trim |
| 21 | 260 | Centessa Pharmaceuticals-adr | -0.2% | -48.74% | Trim |
| 22 | CVEO | Civeo CORP | -0.3% | — | Trim |
| 23 | VRNA | Verona Pharma PLC - Adr | -0.4% | — | Unchanged |
| 24 | TNGX | Tango Therapeutics Inc | -0.6% | -85.34% | Trim |
| 25 | CNDT | Conduent Inc | -1.1% | — | Trim |
| 26 | ELDN | Eledon Pharmaceuticals Inc | -1.2% | -26.32% | Trim |
| 27 | CGEM | Cullinan Therapeutics Inc | -1.3% | +5.24% | Add |
| 28 | OBDC | Blue Owl Capital CORP | -1.6% | — | Unchanged |
| 29 | NCDL | Nuveen Churchill Direct Lend | -8.9% | -23.47% | Trim |
| 30 | TRML | Tourmaline Bio Inc | — | EXIT | Sold out |
| 31 | TQQQ | Proshares Ultrapro Qqq | — | EXIT | Sold out |
| 32 | DELL | Dell Technologies -c | — | NEW | New buy |
| 33 | ✓ | Ikena Oncology Inc | — | EXIT | Sold out |
| 34 | KRRO | Korro Bio Inc | — | NEW | New buy |
| 35 | IMA | Imagenebio Inc | — | NEW | New buy |
| 36 | IMRX | Immuneering CORP - Class A | — | NEW | New buy |
| 37 | ETWOGBP | E2open Parent Holdings Inc | — | EXIT | Sold out |
| 38 | NU | Nu Holdings Ltd. | — | NEW | New buy |
| 39 | KROS | Keros Therapeutics Inc | — | EXIT | Sold out |
| 40 | MREO | Mereo Biopharma Group Pl-adr | — | NEW | New buy |
| 41 | NN | Nextnav Inc | — | EXIT | Sold out |
| 42 | ACLXGBX | Arcellx Inc | — | NEW | New buy |
| 43 | 4XC1 | Kalvista Pharmaceuticals Inc | — | NEW | New buy |
| 44 | FLD | Fold Holdings Inc | — | NEW | New buy |
| 45 | ✓ | Marblegate Acquisition Corp | — | EXIT | Sold out |
| 46 | ✓ | Inozyme Pharma Inc | — | EXIT | Sold out |
| 47 | GOCOQ | Gohealth Inc-class A | — | EXIT | Sold out |
| 48 | GTLB | Gitlab Inc-cl A | — | NEW | New buy |
| 49 | TTAN | Servicetitan Inc-a | — | NEW | New buy |
| 50 | ✓ | — | EXIT | Sold out |
According to official SEC Form 13F filings, Blue Owl Capital Holdings LP reported a total U.S. public equity portfolio value of $664.5M across 72 disclosed positions in Q3 2025.
During Q3 2025, Blue Owl Capital Holdings LP's top holdings by market value included NCDL (13.2%)、OBDC (8.1%)、ENGENE HOLDINGS INC (7.0%). The largest single position, NCDL, represented 13.2% of total portfolio value.
In Q3 2025, Blue Owl Capital Holdings LP made 42 total portfolio adjustments, initiating 11 new buys, adding to 6 positions, trimming 15 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.